Kinetoplastida: New therapeutic strategies

Parasite

Volumn 15, Issue 3, 2008, Pages 522-527

  Croft, S L ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Chagas disease; Chemotherapy; Cutaneous leishmaniasis; Drugs; Human African trypanosomiasis; Visceral leishmaniasis

Indexed keywords

KINETOPLASTIDA; MASTIGOPHORA (FLAGELLATES);

EID: 51149113993     PISSN: 1252607X     EISSN: None     Source Type: Journal    
DOI: 10.1051/parasite/2008153522     Document Type: Conference Paper

References (35)

1. AL-ABDELY H.M., GRAYBILL J.R., LOEBENBERG D. & MELBY P.C. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Antimicrobial Agents and Chemotherapy, 1999, 43, 2910-2914.
2. ANSEDE J.H., ANBAZHAGAN M., BRUN R., EASTERBROOK J.D., HALL J.E. & BOYKIN D.W. O-alkoxyamidine prodrugs of furamidine: in vitro transport and microsomal metabolism as indicators of in vivo efficacy in a mouse model of Trypanosoma brucei rhodesiense infection. Journal of Medicinal Chemistry, 2004, 47, 4335-4338.
3. BALANA-FOUCE R. &, REGUERA R.M. RNA interference in Trypanosoma brucei: a high-throughput engine for functional genomics in trypanosomatids? Trends in Parasitology, 2007, 23, 348-351.
4. BHATTACHARYA S.K., SINHA P.K., SUNDAR S., THAKUR C.P., JHA T.K., PANDEY K., DAS V.R., KUMAR N., LAL C., VERMA N., SINGH V.P., ANDERS G., SINDERMANN H. & GANGULY N.K. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. Journal of Infectious Diseases, 2007, 196, 591-598.
5. BEN SALAH A. et al. WR279396 an efficient non toxic topical treatment of old world cutaneous leishmaniosis. Abstract book - Third World Congress on Leishmaniosis - April 2005, Sicily, Italy.
6. BERN C., ADLER-MOORE J., BERENGUER J., BOELAERT M., DEN BOER M., DAVIDSON R.N., FIGUERAS C., GRADONI L., KAFETZIS D.A., RITMEIJER K., ROSENTHAL E., ROYCE C., RUSSO R., SUNDAR S. & ALVAR A. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clinical Infectious Diseases, 2006, 43, 917-924
7. BRUN R., SCHUMACHER R., SCHMID C., KUNZ C. & BURRI C. The phenomenon of treatment failures in human African trypanosomiasis. Tropical Medicine & International Health, 2001, 6, 906-914.
8. BERRIMAN M et al. The genome of the African trypanosome Trypanosoma brucei. Science, 2005, 309, 416-422.
9. BURRI C. & BRUN R. Eflornithine for the treatment of human African trypanosomiasis. Parasitology Research, 2003, 90 (Supp. 1), S49-S52.
10. CAZZULO J.J. PROTEINASES of Trypanosoma cruzi: patential targets for the chemotherapy of Chagas disease. Current Topics Medicinal Chemistry, 2002, 2, 1261-1271.
11. CHAPPUIS F., UDAYRAJ N., STIETENROTH K., MEUSSEN A. & BOVIER P.A. Eflornithine is safer than melarsoprol for the treatment of the second stage Trypanosoma brucei gambiense human African trypanosomiasis. Clinical Infectious Diseases, 2005, 41, 748-751.
12. CROFT S.L. & ENGEL J. Miltefosine-discovery of the antileishmanial activity of phospholipid derivatives. Transactions of the Royal Society of Tropical Medicine, 2006, 100, S4-S8.
13. CROFT S.L., SUNDAR S. & FAIRLAMB A.H. Drug resistance in leishmaniasis. Clinical Microbiological Reviews, 2006, 19, 111-126.
14. DOYLE P.S., ZHOU Y.M., ENGEL J.C. & MCKERROW J.H. A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-moiuse model of infection. Antimicrobial Agents and Chemotherapy, 2007, 51, 3932-3939.
15. EL-SAYED N.M. et al. Comparative genomics of trypanosomatid parasitic protozoa. Science. 2005, 309, 404-409.
16. FREARSON J.A., WYATT P.G., GILBERT I.H. & FAIRLAMB A.H. Target assessment for antiparasitic drug discovery. Trends in Parasitology, 2007, 23, 589-595.
17. GARZONI L.R., WAGHABI M.C., BAPTISTA M.M., DE CASTRO S.L., MEIRELLES MDE N., BRITTO C.C., DOCAMPO R., OLDFIELD E. & URBINA J.A. Antiparasitic activity of risedronate in a murine model of acute Chagas' disease. International Journal of Antimicrobial Agents, 2004, 23, 286-290.
18. GRANT K.M., DUNION M.H., YARDLEY V., SKALTSOUNIS A.L., MARKO D., EISENBRAND G., CROFT S.L., MEIJER L. & MOTTRAM J.C. Inhibitors of Leishmania mexicina CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity. Antimicrobial Agents and Chemotherapy, 2004, 48, 3033-3042.
19. LUSCHER A., DE KONING H.P. & MASER P. Chemotherapeutic strategies against Trypanosoma brucei; drug targets vs. drug targeting. Current Pharmaceutical Research, 2007, 13, 555-567.
20. MAES L., GERMONPREZ N., QUIRIJNEN L., VAN PUYVELDE L., COS P. & VANDEN BERGHE D. Comparative activities of the triterpene saponin maesabalide III and liposomal amphotericin B (AmBisome) against Leishmania donovani in hamsters. Antimicrobial Agents and Chemotherapy, 2004, 48, 2056-2060.
21. MOLINA J., MARTINO-FILHO O., BRENER Z., ROMANHA A.J., LOEBENBERG D. & URBINA J.A. Activities of the triazole SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts. Antimicrobial Agents and Chemotherapy, 2000, 44, 150-155.
22. NAKAYAMA H., LOISEAU P.M., BORIES C., TORRES DE ORTIZ S., SCHININI A., SERNA E., ROJAS DE ARIAS A., FAKHFAKH M.A., FRANCK X., FIGADERE B., HOCQUEMILLER R. & FOURNET A. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases. Antimicrobial Agents and Chemotherapy, 2005, 49, 4950-4956.
23. ROBERTS C.W., MCCLEOD R., RICE D.W., GINGER M., CHANCE M.L. & GOAD L.J. Fatty acid and sterol metabolism: potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Molecular and Biochemical Parasitololgy, 2003, 126, 129-142.
24. SCHMID C., NKUNKU S., MEROLLE A., VOUNATOSU P. & BURRI C. Efficacy of 10-day melarsoprol schedule two years after treatment for late-stage gambiense sleeping sickness. Lancet, 2004, 364, 789-790.
25. SOSA-ESTANI S., SEGURA E.L., RUIZ A.M., VELAZQUEZ E., PORCEL B.M. & YAMPOTIS C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. American Journal of Tropical Medicine and Hygiene, 1998, 59, 526-529.
26. SHAPIRO T.A., WERE J.B., DAUSO K., NELSON D.J., DESJARDINS R.E. & PAMPLIN C.L. Pharmacokinetics and metabolism of allopurinol riboside. Clinical Pharmacology Therapeutics, 1991, 49, 506-514.
27. SOTO J., ARANA B.A., TOLEDO J., RIZZO N., VEGA J.C., DIAZ A., LUZ M., GUTIERREZ P., ARBOLEDA M., BERMAN J.D., JUNGE K., ENGEL J. & SINDERMANN H. Miltefosine for new world cutaneous leishmaniasis. Clinical Infectious Diseases, 2004, 38, 1266-1272.
28. STEWART M.L., BUENO G.J., BALIANI A., KLENKE B., BRUN R., BROCK J.M., GILBERT I.H. & BARRETT M.P. Trypanocidal activity of melamine-based nitroheterocycles. Antimicrobial Agents and Chemotherapy, 2004, 48, 1733-1738.
29. SUNDAR S., JHA T.K., THALUR C.P., MISHRA M., SINGH V.P. & BUFFELS R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clinical Infectious Diseases, 2003, 37, 800-804.
30. SUNDAR S., JHA T.K., THAKUR C.P., SINHA P.K. & BHATTACHARYA S.K. Injectable paromomycin for visceral leishmaniasis in India. New England Journal of Medicine, 2007, 356, 2571-2578.
31. TARLETON R.L. Parasite persistence in the aetiology of Chagas disease. International Journal for Parasitology, 2001, 31, 550-554.
32. URBINA J.A. & DOCAMPO R. Specific chemotherapy of Chagas disease: controversies and advances. Trends in Parasitology, 2003, 19, 495-501.
33. YARDLEY V., CROFT S.L., DE DONCKER S., DUJARDIN J.C., KOIRALA S., RIJAL S., MIRANDA C., LLANOS-CUENTAS A. & CHAPPUIS F. The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. American Journal of Tropical Medicine and Hygiene, 2005, 73, 272-275.
34. YARDLEY V., KHAN A.A., MARTIN M.B., SLIFER T.R., ARAUJO F.G., MORENO S.N.J., DOCAMPO R., CROFT S.L. & OLDFIELD E. In vivo activity of the farnesyl pyrophosphate inhibitors aledronate, pamidronate and risedronate against Leishmania donovani and Toxoplasma gondii. Antimicrobial Agents and Chemotherapy, 2002, 46, 929-931.
35. ZHAI L., CHEN M., BLOM J., THEANDER T.G., CHRISTENSEN S.B. & KHARAZMI A. The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. Journal of Antimicrobial Chemotherapy, 1999, 43, 793-803.